Skip to content

A verification study of the test food intake on liver function

A verification study of the test food intake on liver function: a randomized, open study - A verification study of the test food intake on liver function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000054373
Enrollment
18
Registered
2024-05-11
Start date
2024-05-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: 12 weeks Test food: Tablet containing plant extract Administration: Take two tablet per day *Daily dose should be taken within the day. If you forget to take the test food, take it as s

Sponsors

Oryza Oil & Fat Chemical Co. Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Subjects aged 20 or more 4. Healthy subjects 5. Subjects who are judged as eligible to participate in study by the physician 6. Subjects whose liver marker are normal (20<=ALT<=30), slightly high (31<=ALT<=50) or high (51<= ALT)

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily use 5. Subjects who currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, lactation, or planning to become pregnant 8. Subjects who suffer from COVID-19 9. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 10. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
The measured value of the ALT (GPT) at 12 weeks after consumption

Secondary

MeasureTime frame
1. The measured value of the ALT (GPT) at four and 8 weeks after consumption 2. The measured value of AST (GOT), gamma-GT (gamma-GTP), LDL cholesterol, total cholesterol, triglyceride at four, 8 and 12 weeks after consumption 3. The questionnaire on fatigue at four, 8 and 12 weeks after consumption

Countries

Japan

Contacts

Public ContactNorihito Shimizu

Oryza Oil & Fat Chemical Co. Ltd Planning & Solution Development Department

kaihatsu@mri.biglobe.ne.jp0586-86-5141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026